Business Team Investment Entrepreneur Trading Concept

Halozyme Therapeutics, Inc. [NASDAQ: HALO] gained by 2.70% on the last trading session, reaching $18.99 price per share at the time. Halozyme Therapeutics, Inc. represents 145.23M in outstanding shares, while the company has a total market value of $2.69B with the latest information.

The Halozyme Therapeutics, Inc. traded at the price of $18.99 with 1.19 million shares were bought and sold during the latest trading session. Over the period of the last 3 months, the average trading volume of HALO shares recorded 1.27M.

Halozyme Therapeutics, Inc. [NASDAQ:HALO]: Analyst Rating and Earnings

Its stock price has been found in the range of 13.24 to 18.74. This is compared to its latest closing price of $18.49.

Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Coming Soon..   ).

Fundamental Analysis of Halozyme Therapeutics, Inc. [HALO]

Now let’s turn to look at profitability: with a current Operating Margin for Halozyme Therapeutics, Inc. [HALO] sitting at -74.76 and its Gross Margin at +93.33, this company’s Net Margin is now -23.50%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is -28.89, and its Return on Invested Capital has reached -18.60%. Its Return on Equity is -35.14, and its Return on Assets is -16.73. These metrics suggest that this Halozyme Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Halozyme Therapeutics, Inc. [HALO] has generated a Total Debt to Total Equity ratio of 50.78. Similarly, its Total Debt to Total Capital is 33.68, while its

Total Debt to Total Assets stands at 28.71. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -6.29, and its Long-Term Debt to Total Capital is 14.01.

What about valuation? This company’s Enterprise Value to EBITDA is -20.16. The Enterprise Value to Sales for this firm is now 11.06, and its Total Debt to Enterprise Value stands at 0.07. Halozyme Therapeutics, Inc. [HALO] has a Price to Book Ratio of 8.51.

Shifting the focus to workforce efficiency, Halozyme Therapeutics, Inc. [HALO] earns $540,434 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.83 and its Total Asset Turnover is 0.32. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.71 and its Current Ratio is 2.86. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Halozyme Therapeutics, Inc. [HALO] has 145.23M shares outstanding, amounting to a total market cap of $2.69B. Its stock price has been found in the range of 13.24 to 18.74. At its current price, it has moved up by 1.33% from its 52-week high, and it has moved up 43.43% from its 52-week low.

This stock’s Beta value is currently 1.82, which indicates that it is 5.23% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 77.53. This RSI suggests that Halozyme Therapeutics, Inc. is currently Overbought.

Conclusion: Is Halozyme Therapeutics, Inc. [HALO] a Reliable Buy?

Shares of Halozyme Therapeutics, Inc. [HALO], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.